China expects clinical trials of omikron vaccine to be completed within 3-4 months before gradually deploying.
Today (28 April 65) the developer of a vaccine once morest COVID-19 to extract the Omicron strain, especially from China, revealed Clinical trials of the vaccine are expected to be completed within three to four months before gradually deploying.
Zhang Yuntao, chief scientist and vice president of Sino Farm’s China National Biotech Group (CNBG), said online. Pre-clinical research in humans found that The vaccine was able to neutralize the activity of the Omicron strain virus.
The results of animal testing also indicate that This vaccine partially protects once morest infection with the Omicron virus. Its protective efficacy will be further observed in clinical trials. This is a procedure approved by the China National Administration of Medicine on Tuesday (April 26).
Xinhua news agency reported that The clinical trial will use a randomized study method. Two-way concealment and a follow-up form for people aged 18 years and over who have had 2-3 doses of the COVID-19 vaccine to assess the safety and immunization capabilities of the fixed-inactivated vaccine.
Yang Huichuan, chief scientist and vice president of the company, said it would coordinate production and key equipment. to produce a vaccine once morest this type of omikron virus. After the vaccine was developed successfully
Picture from : AFP
